FL118 Degrades Two Cancer Proteins Simultaneously, Targeting Treatment-Resistant Tumors
For patients facing cancers that have exhausted standard treatment options — pancreatic adenocarcinoma, glioblastoma, castration-resistant prostate cancer — th…
Found 1467 results for "cancer"
For patients facing cancers that have exhausted standard treatment options — pancreatic adenocarcinoma, glioblastoma, castration-resistant prostate cancer — th…
A decade after the first FDA approval of CDK4/6 inhibitors, oncology stands at a meaningful inflection point — one where the foundational lessons from breast c…
A comprehensive NIH-authored compendium identifies circulating senescence-associated secretory phenotype (SASP) factors — particularly GDF15 and Activin A — as…
Early-onset cancer — diagnosed before age 50 — has been climbing globally for decades, and the explanation has remained frustratingly incomplete. Genetic predi…
For decades, KRAS was considered undruggable — a death sentence for patients whose tumors carried mutations in this master oncogene, which drives roughly a qua…
Understanding how nascent tumors escape the physical constraints of healthy tissue is one of cancer biology's most consequential unsolved problems — and new me…
How cancer cells manage their molecular communications under duress has long been a blind spot in tumor biology — and closing that gap could reshape therapeuti…
Drug resistance remains the central unsolved problem in multiple myeloma, a blood cancer where most patients eventually relapse despite initial responses to mo…
Early cancer detection has long been constrained by a paradox: the cancers most likely to be cured are often the hardest to catch before symptoms appear. A blo…
Early cancer detection sounds like an unambiguous win, but the gap between a compelling premise and proven clinical benefit is precisely where medicine has bee…
A near-comprehensive national dataset revealing that substance use disorders carry a dramatically elevated mortality burden should prompt any health-conscious…
Ovarian cancer remains one of the most lethal gynecologic malignancies partly because it is rarely detected early — which is why any intervention that meaningf…
For the millions of women navigating breast cancer prevention, dietary choices remain one of the few modifiable levers available. A large prospective cohort no…
For immunocompromised patients — transplant recipients, cancer patients on chemotherapy, ICU patients on broad-spectrum antibiotics — invasive Candida infectio…
One of the most stubborn problems in oncology is cancer cells that learn to survive the very drugs designed to kill them. Multiple myeloma, a blood cancer noto…
Appendiceal adenocarcinoma is one of oncology's orphan diseases — so rare that standard chemotherapy regimens borrowed from colorectal cancer are used largely…
For decades, the proteins that control which genes get switched on or off inside cancer cells were considered essentially untouchable by conventional drugs — t…
For one of the most difficult-to-treat abdominal cancers, identifying who will relapse early after aggressive combined treatment has been an unsolved clinical…
For women carrying BRCA1 or BRCA2 mutations, the calculus of cancer prevention has long forced a brutal trade-off: remove the ovaries early and slash cancer ri…
Cancer treatment side effects — pain, anxiety, nausea, depression — remain undertreated in conventional oncology, partly because integrative modalities like ac…